Skip to content
BOLUS

Signal from the log

Infinimmune

75 M$ · Series A · United States · Biotech

Biotech d'Alameda, en Californie, qui conçoit des anticorps monoclonaux à partir de cellules B humaines réelles plutôt que de modèles murins, sur sa plateforme Anthrobody. Ses deux candidats IFX-201 et IFX-101 visent la dermatite atopique chez les patients que les traitements existants ne soulagent pas.

Verified

Announced on , logged by the watch of 11 August 2026.

Operation
Funding round
Announced amount
75 M$
Stage
Series A
Country
United States
Sector
Biotech

What the log says

Editorial note, in French

Communiqué ouvert, montant relu et fonds nommés.

The investors

Led by Regeneron Ventures , Playground Global , with RA Capital Management , Goldcrest Capital , Forge Life Science Partners , Godfrey Capital , Wild Tree Ventures , Merck Global Health Innovation Fund , Everbright Biofund , Civilization Ventures , Pear VC

Provenance
Source endpoints,medcity
Logged on 11 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.

One address, nothing else.

One letter a week, on Fridays: the week's funding rounds, the funds named, the amounts double checked. The list is never sold, one click to unsubscribe. The letter is written in French.

Email confirmation before any subscription. The list is never sold. What Bolus knows about you is written on the privacy page (in French).